DCT and cancer: The efficacy of CMV as a cancer vaccine vector has been demonstrated in several preclinical models by using MCMV vectors containing prostate specific antigen (PSA), melanoma antigens (gp100, tyrosinase-related protein-2 (TRP-2)) or model antigens (ovalbumin) [8–11].